Vertex Pharmaceuticals (VRTX) Stock Price, Quote, News & History | Benzinga

Vertex Pharmaceuticals Inc (VRTX) — Q2 FY26 Earnings Call Live coverage with Benzinga. Q2 FY26 Results EPS: $4.73 (est. $4.63) — inline Revenue: $3.33B (est. $3.21B) — inline Reported: 2026-08-03 Recent Quarters Q1 FY26 (2026-05-04): EPS $4.47 vs est $4.18 · Rev $2.99B vs est $2.99B Q4 FY25 (2026-02-12): EPS $5.03 vs est $4.85 · Rev $3.19B vs est $3.17B Q3 FY25 (2025-11-03): EPS $4.80 vs est $4.35 · Rev $3.08B vs est $3.05B Q2 FY25 (2025-08-04): EPS $4.52 vs est $4.05 · Rev $2.96B vs est $2.90B About Vertex Pharmaceuticals Inc Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. https://www.vrtx.com · Boston, MA, USA · 6,400 employees Follow Benzinga X: https://x.com/Benzinga Facebook: https://www.facebook.com/Benzinga/ Instagram: https://www.instagram.com/benzinga/ ⚠️ Disclaimer: Investing in financial markets carries risk, and there are no guaranteed returns. All information is for educational purposes only and should not be taken as financial advice. Always do your own research and speak with a qualified financial advisor before making investment decisions. Only invest what you can afford to lose. Past performance does not guarantee future outcomes. #earnings #VRTX #stocks #benzinga